RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Avadel Pharmaceuticals P/E 2024

Avadel Pharmaceuticals P/E

-31.59

Avadel Pharmaceuticals Dividend yield

Ticker

AVDL

ISIN

US05337M1045

WKN

A2DJR8

As of May 19, 2024, Avadel Pharmaceuticals's P/E ratio was -31.59, a 351.29% change from the -7 P/E ratio recorded in the previous year.

The Avadel Pharmaceuticals P/E history

Avadel Pharmaceuticals Aktienanalyse

What does Avadel Pharmaceuticals do?

Avadel Pharmaceuticals PLC is an Irish pharmaceutical company that focuses on the development, manufacturing, and marketing of pharmaceutical products. The company was founded in 1999 under the name Flamel Technologies and was renamed Avadel Pharmaceuticals in 2019 to support its rebranding strategy and expand its activities in the global market. Avadel's business model is based on the discovery and development of therapies for rare diseases and sleep-related disorders, as well as the manufacturing and marketing of generic drugs and specialty products. The company is divided into three main segments: specialty pharmaceuticals, generic pharmaceuticals, and the Pediarix division. Avadel's specialty pharmaceuticals segment focuses on developing drugs for patients with rare diseases such as Prader-Willi syndrome or narcolepsy. An example of an innovative product in this segment is Rekarbri, an ORP medication for the treatment of narcolepsy. It is the first drug in the EU specifically tailored to the specific needs of narcolepsy patients and has improved patients' quality of life. The generic pharmaceuticals segment of Avadel offers high-quality and cost-effective medications that treat commonly prescribed and everyday conditions such as pain, infections, depression, and anxiety disorders. Most products in this segment are manufactured in the USA and are available in many countries worldwide. Avadel's Pediarix division specializes in the development and manufacturing of children's medicines. This includes products for the treatment of attention deficit/hyperactivity disorder (ADHD) and autism spectrum disorders (ASD). An example of a product from this segment is Reagila, a medication for the treatment of ADHD in children that is known for its improved efficacy and lower risk of side effects. Avadel also has a geographically distributed business structure that allows it to market its products worldwide. The company has a strong presence in the USA and is represented in Europe, Asia, and Australia. It has an impressive research and development infrastructure, including manufacturing facilities and research facilities, that allow it to meet the needs of its customers. Overall, Avadel Pharmaceuticals is a leading pharmaceutical company that focuses on researching new and innovative therapies for patients with rare diseases and sleep-related disorders. The company has demonstrated its ability to bring effective products to the market while maintaining the highest standards in quality assurance and customer service. It is expected that Avadel will continue to grow in the future and introduce new and innovative products to help its customers and patients worldwide. Avadel Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Avadel Pharmaceuticals's P/E Ratio

The Price to Earnings (P/E) Ratio of Avadel Pharmaceuticals is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Avadel Pharmaceuticals's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Avadel Pharmaceuticals is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Avadel Pharmaceuticals’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Avadel Pharmaceuticals Stock

What is the price-to-earnings ratio of Avadel Pharmaceuticals?

The price-earnings ratio of Avadel Pharmaceuticals is currently -31.59.

How has the price-earnings ratio of Avadel Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Avadel Pharmaceuticals has increased by 351.29% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Avadel Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Avadel Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Avadel Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Avadel Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Avadel Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Avadel Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Avadel Pharmaceuticals?

Some factors that influence the price-earnings ratio of Avadel Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Avadel Pharmaceuticals pay?

Over the past 12 months, Avadel Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Avadel Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Avadel Pharmaceuticals?

The current dividend yield of Avadel Pharmaceuticals is .

When does Avadel Pharmaceuticals pay dividends?

Avadel Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Avadel Pharmaceuticals?

Avadel Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Avadel Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Avadel Pharmaceuticals located?

Avadel Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Avadel Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Avadel Pharmaceuticals from 5/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/19/2024.

When did Avadel Pharmaceuticals pay the last dividend?

The last dividend was paid out on 5/19/2024.

What was the dividend of Avadel Pharmaceuticals in the year 2023?

In the year 2023, Avadel Pharmaceuticals distributed 0 USD as dividends.

In which currency does Avadel Pharmaceuticals pay out the dividend?

The dividends of Avadel Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Avadel Pharmaceuticals

Our stock analysis for Avadel Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Avadel Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.